De-risk CNS Drug Development with Preclinical and Translational imaging Services

Visualize biodistribution, brain activity, and target engagement with advanced in vivo CNS imaging solutions designed to accelerate preclinical and translational neuroscience programs.

Home

Your Partner for Preclinical Neuroscience and CNS Imaging

As a preclinical neuroscience CRO, Perceptive Discovery provides comprehensive preclinical CNS imaging services that generate high-resolution, translational insights. From biodistribution and occupancy studies to volumetric imaging and gene therapy visualization, our integrated radiochemistry and imaging teams help drug developers make informed, data-driven decisions earlier in their neuroscience pipeline.

We support programs across multiple CNS indications, including Alzheimer’s disease, Parkinson’s disease, depression, and neuroinflammation,enabling smarter discovery and IND-enabling studies for small molecules, biologics, and gene or RNA therapies.

Comprehensive In Vivo CNS Imaging Expertise

11,000+ studies completed, including neurology and neurodegeneration models
Full suite of in vivo CNS imaging modalities: PET, SPECT, MRI, CT, BLI, FMRI, cryofluorescence tomography (CFT)
Quantitative biomarker imaging for target engagement, neurotransmitter release, and volumetric brain analysis
Experience with small molecules, ASOs, siRNA, antibodies, and viral vectors (e.g., AAVs)
Multi-species expertise: rodents, non-human primates, and transgenic models

CNS Imaging Services Built for Translational Impact

How Can We Help?

Reach out today and one of our solution experts will be in touch to learn about your specific needs.

"*" indicates required fields

Facebook

This field is for validation purposes and should be left unchanged.

First name*

Last name*

Job title*

Company name*

Your Location*

State

Business email*

Project description*

CAPTCHA

By subscribing, you consent to receive emails from Perceptive. We respect your privacy and you can manage your communication preferences anytime. You can find the Perceptive privacy policy here.

Radiochemistry & Molecular Imaging for CNS Applications

Perceptive Discovery integrates radiolabeling chemistry and molecular imaging to advance neuroscience programs

Our preclinical neuroscience CRO platform offers end-to-end support from tracer design through imaging execution

Access to short- and long-lived radioisotopes: C-11, F-18, I-125, Tc-99m
Labeling of small molecules, antibodies, ASOs, AAVs, siRNA, and novel ligands
QC, purification, bioactivity testing, and stability analysis
Dual in vivo/ex vivo workflows for enriched spatial and temporal resolution

Learn more about our radiochemistry services

Radionuclide Experience

Application	Radionuclide
PET	¹⁸F ¹⁸F (GMP) ⁶⁴Cu ¹¹C (GMP) ⁶⁸Ga ⁸⁹Zr ⁸⁹Zr (GMP) ¹²⁴\| ⁸⁶y ⁵²Mn
SPECT half life <24 h	^99mTc ¹²³\| ¹²³\| (GMP) ^99mTc (GMP)
SPECT long-lived	⁶⁷Ga ⁷⁵Se ¹¹¹\|n ¹²⁵\| ²⁰³Pb ⁶⁷Cu
Alpha Therapeutics	²²⁵Ac ²¹¹At ²¹²Pb
Beta Therapeutics	/sup>177Lu ¹⁸⁶Re ¹⁸⁸Re ¹⁶¹Tb ⁹⁰y ¹³¹\| ⁶⁷Cu
Low energy beta emitters	³H ¹⁴℃ ³²P ³⁵S

Select Beta emitter (3H 14C) labeling is outsourced
Other radionuclides available on request
Non-metals for PET: 11C 13N 150 18F 124|
Non-metals for SPECT: 123| 1251

Therapeutic Areas & Imaging Capabilities

Purpose-Built Solutions for CNS Programs

Research Focus	Capabilities
Target Occupancy & Dose Optimization	PET, autoradiography, in vivo dose-occupancy curves
Gene & RNA Therapy Imaging	Biodistribution, transduction, expression tracking via PET, SPECT, CFT, IHC
Neurodegeneration & Atrophy Analysis	DTI, volumetric MRI, cortical mapping, tractography
Neurotransmitter Activity & PK/PD	Dopamine, serotonin, opioid release studies via MRS and PET
Biomarker Discovery & Validation	Custom radioligand development, receptor binding, Quanticell™ IHC